Compare VITL & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VITL | TBPH |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.3M | 1.0B |
| IPO Year | 2020 | 2013 |
| Metric | VITL | TBPH |
|---|---|---|
| Price | $20.04 | $13.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $42.56 | $20.20 |
| AVG Volume (30 Days) | ★ 2.1M | 675.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.03 | N/A |
| EPS | ★ 1.44 | 0.88 |
| Revenue | ★ $759,444,000.00 | $15,386,000.00 |
| Revenue This Year | $26.07 | $70.90 |
| Revenue Next Year | $20.95 | N/A |
| P/E Ratio | ★ $13.90 | $15.55 |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $19.75 | $7.90 |
| 52 Week High | $53.13 | $21.03 |
| Indicator | VITL | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 23.17 | 22.48 |
| Support Level | N/A | $13.58 |
| Resistance Level | $31.02 | $14.76 |
| Average True Range (ATR) | 1.24 | 0.93 |
| MACD | -0.58 | -0.66 |
| Stochastic Oscillator | 3.04 | 7.31 |
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).